Skip to main content
GENFIT logo

GENFIT — Investor Relations & Filings

Ticker · GNFT ISIN · FR0004163111 LEI · 969500XPWN2DMZQA5X73 PA Professional, scientific and technical activities
Filings indexed 681 across all filing types
Latest filing 2018-12-03 Regulatory Filings
Country FR France
Listing PA GNFT

About GENFIT

https://www.genfit.com

GENFIT is a biopharmaceutical company dedicated to developing therapeutic and diagnostic solutions for patients with rare and severe liver diseases characterized by high unmet medical needs. The company's primary focus is on Acute-on-Chronic Liver Failure (ACLF) and its associated conditions, such as acute decompensation (AD) and hepatic encephalopathy (HE). Leveraging a scientific heritage of over two decades, GENFIT is a pioneer in liver disease research and development, aiming to improve the lives of patients with these life-threatening conditions.

Recent filings

Filing Released Lang Actions
2018.12.03 - NTZ Launch - PR EN
Regulatory Filings Classification · 95% confidence The document is a press release dated December 3, 2018, announcing the launch of a Phase 2 clinical study for nitazoxanide in NASH patients. It details the study objectives, the investigator, the scientific rationale (preclinical data), and includes quotes from management. This format—a formal announcement of a significant corporate/clinical development event, often issued via press release—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is not a full financial report (10-K, IR), a transcript (CT), or a specific management discussion (MDA), and it announces a key operational event (clinical trial initiation), it fits best as a general announcement. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a press release announcing clinical progress that doesn't fit a more specific category like 'Earnings Release' (ER) or 'Capital Update' (CAP). However, because it is a formal announcement of a significant business event, it often overlaps with the function of an ER, but ER is defined as 'Initial announcement of quarterly/periodical financial results (key highlights only)'. This is not financial results. Therefore, RNS is the best fit as a general regulatory/corporate announcement.
2018-12-03 English
2018.11.19 PR Confidential Submission
Capital/Financing Update Classification · 98% confidence The document is explicitly titled "PRESS RELEASE" and announces that GENFIT plans to conduct a "registered public offering of its ordinary shares, in the form of American Depositary Shares ('ADSs'), in the United States" and has submitted a draft registration statement on Form F-1 to the SEC. This action directly relates to fundraising, financing activities, and capital structure changes (issuing new shares/ADSs). Therefore, the most appropriate classification is Capital/Financing Update (CAP). It is not a full 10-K, an Earnings Release (ER), or a standard regulatory filing (RNS) because it describes a specific financing event.
2018-11-19 English
2018.11.19 CP Soumission Confidentielle
Share Issue/Capital Change Classification · 99% confidence The document is explicitly titled 'COMMUNIQUÉ DE PRESSE' (Press Release) and announces the company's 'intention de procéder à une offre au public' (intention to proceed with a public offering) of its shares in the US, including the confidential submission of a Form F-1 to the SEC. This action relates directly to fundraising and capital structure changes. While it discusses a future financing event, the immediate nature of the announcement (a press release about the intent to raise capital) aligns best with the 'Capital/Financing Update' category (CAP). It is not the final prospectus or the actual capital change filing, but the announcement initiating the process.
2018-11-19 French
2018.06.18 PR GENFIT Results Shareholders Meeting
Declaration of Voting Results & Voting Rights Announcements Classification · 98% confidence The document is explicitly titled 'PRESS RELEASE' and its primary content details the 'OUTCOME OF THE ORDINARY AND EXTRAORDINARY SHAREHOLDERS' MEETING OF JUNE 15, 2018'. It reports on the adoption of resolutions and provides voting details from a general meeting. This directly corresponds to the definition of 'Declaration of Voting Results & Voting Rights Announcements' (DVA). Although it is a press release, the specific content dictates the classification over a general 'RPA' or 'RNS'.
2018-06-18 English
2018.06.18 CP GENFIT Résultats AG
AGM Information Classification · 99% confidence The document is titled "COMMUNIQUÉ DE PRESSE" (Press Release) and explicitly states its purpose: "GENFIT : RESULTATS DE L'ASSEMBLEE GENERALE ORDINAIRE ET EXTRAORDINAIRE DU 15 JUIN 2018" (GENFIT: RESULTS OF THE ORDINARY AND EXTRAORDINARY GENERAL MEETING OF JUNE 15, 2018). It details the voting results for various resolutions presented at the AGM. This content directly relates to the outcomes of a shareholder meeting. The most specific category for official results from shareholder votes at a general meeting is 'Declaration of Voting Results & Voting Rights Announcements' (DVA). Although it is a press release announcing the results, the core content is the voting outcome, making DVA more precise than a general RPA or RNS.
2018-06-18 French
2018.05.31 PR GENFIT - Pascal Prigent
Board/Management Information Classification · 99% confidence The document is explicitly titled "PRESS RELEASE" and announces the appointment of a new Executive Vice President, Pascal Prigent. This type of announcement concerns changes in senior management personnel. Reviewing the definitions, the category 'Board/Management Information (Code: MANG)' covers 'Announcement of changes in the company's board of directors or senior management.' This is a direct match. The document is not a full financial report (10-K, IR), an earnings release (ER), or a proxy statement (DEF 14A/PSI).
2018-05-31 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.